0000899243-17-025636.txt : 20171108
0000899243-17-025636.hdr.sgml : 20171108
20171108180454
ACCESSION NUMBER: 0000899243-17-025636
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171106
FILED AS OF DATE: 20171108
DATE AS OF CHANGE: 20171108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GIANAKAKOS ANASTASIOS
CENTRAL INDEX KEY: 0001413822
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37609
FILM NUMBER: 171187761
MAIL ADDRESS:
STREET 1: 333 ALLERTON AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MyoKardia Inc
CENTRAL INDEX KEY: 0001552451
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455500552
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-741-0900
MAIL ADDRESS:
STREET 1: 333 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-06
0
0001552451
MyoKardia Inc
MYOK
0001413822
GIANAKAKOS ANASTASIOS
C/O MYOKARDIA, INC.
333 ALLERTON AVENUE
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
Common Stock
2017-11-06
4
M
0
4300
1.5068
A
513417
D
Common Stock
2017-11-06
4
S
0
3200
40.2469
D
510217
D
Common Stock
2017-11-06
4
S
0
1100
40.1818
D
509117
D
Common Stock
181169
I
By Reporting Person's Trust
Stock Option (Right to Buy)
1.5068
2017-11-06
4
M
0
4300
0.00
D
2025-06-03
Common Stock
4300
157912
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Represents the weighted average sale price of the shares sold ranging from $39.95 to $40.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average sale price of the shares sold ranging from $40.95 to $41.30 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
25% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019.
/s/ Jake Bauer, Attorney-in-Fact
2017-11-08